Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
41 pending office actions • 9 clients • 37 examiners • 21 art units • 0 of 41 (0%) have an AI response strategy ready • 55 patents granted in the last 365 days
Lathrop GPM LLP | Sanofi-Aventis focuses its practice on the Biotechnology & Pharmaceuticals technology area, drawing on a history of 6785 career applications. The firm maintains a resolved allowance rate of 83.27 percent, demonstrating the percentage of its applications that reach a grant. This total of 6785 career applications provides a basis for the firm's experience in handling life sciences disclosures.
The firm's prosecution process involves an average of 3.48 office actions per allowance. This metric indicates the typical number of interactions between the firm and patent examiners before an application reaches an allowance. Currently, the firm is managing 34 pending office actions, which represents the volume of its active prosecution docket in the Biotechnology & Pharmaceuticals sector. These 34 pending office actions are fewer than the 6785 career applications on record.
The 83.27 percent allowance rate and the 3.48 office actions per allowance offer specific metrics for evaluating prosecution timelines. The 34 pending office actions show the firm's current focus, while the 6785 career applications document its historical involvement in the field. These figures provide a data-grounded view of the firm's activity and results.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (10%) |
| §103 only | 8 (20%) |
| §112 only | 7 (17%) |
| Double-patenting only | 3 (7%) |
| Double-patenting + other | 12 (29%) |
| Multi-statute (no §101) | 6 (15%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POPA, ILEANA | 2 | 21.4% | +15.1% |
| LI, RUIXIANG | 2 | 59.5% | +18.6% |
| BRETZ, COREY LANE | 2 | 0.0% | +0.0% |
| HUYNH, PHUONG N | 2 | 65.7% | +53.6% |
| CHORBAJI, MONZER R | 1 | 76.4% | +21.3% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
| PIPIC, ALMA | 1 | 54.6% | +54.7% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 127d overdue |
| 18016625 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | ROZOF, TIMOTHY R | 6d |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 9d |
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | 56d |
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | — |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18741976 | LYME DISEASE RNA VACCINE | OGUNBIYI, OLUWATOSIN A | — |
| 18634191 | PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-OX40L ANTIBODIES | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 9d |
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | — |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18888602 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | AUDET, MAURY A | — |
| 18729020 | LIPIDIC COMPOUNDS, AND USES THEREOF | PIPIC, ALMA | — |
| 18741976 | LYME DISEASE RNA VACCINE | OGUNBIYI, OLUWATOSIN A | — |
| 18668446 | HUMANIZED ANTI-IL-1R3 ANTIBODIES | LI, RUIXIANG | — |
| 18656168 | METHODS OF TREATING HEMOPHILIA A | SABILA, MERCY HELLEN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| TRANSLATE BIO, INC. | 10 |
| Sanofi | 9 |
| REGENERON PHARMACEUTICALS, INC. | 7 |
| Bioverativ Therapeutics | 5 |
| GENZYME CORPORATION | 5 |
| KYMAB LIMITED | 2 |
| Kymab | 1 |
| Ablynx | 1 |
| miRecule | 1 |
| Art Unit | Apps |
|---|---|
| 1641 | 5 |
| 1643 | 3 |
| 1637 | 2 |
| 1674 | 2 |
| 1683 | 2 |
| 1633 | 2 |
| 1634 | 2 |
| 1654 | 1 |
| 1617 | 1 |
| 1645 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | BIOVERATIV THERAPEUTICS INC. | CHORBAJI, MONZER R | §102§103 | Non-Final OA | — | Pending | Oct 01, 2024 | |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | Translate Bio, Inc. | POPA, ILEANA | §101§103§112Other | Non-Final OA | — | Pending | Sep 20, 2024 | |
| 18888602 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | Sanofi | AUDET, MAURY A | 1654 | §112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18729020 | LIPIDIC COMPOUNDS, AND USES THEREOF | Sanofi | PIPIC, ALMA | 1617 | §112 | Final Rejection | — | Pending | Jul 15, 2024 |
| 18741976 | LYME DISEASE RNA VACCINE | Sanofi Pasteur Inc. | OGUNBIYI, OLUWATOSIN A | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18668446 | HUMANIZED ANTI-IL-1R3 ANTIBODIES | Sanofi Biotechnology | LI, RUIXIANG | §112 | Non-Final OA | — | Pending | May 20, 2024 | |
| 18656168 | METHODS OF TREATING HEMOPHILIA A | BIOVERATIV THERAPEUTICS INC. | SABILA, MERCY HELLEN | §102§103DP | Non-Final OA | — | Pending | May 06, 2024 | |
| 18634191 | PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-OX40L ANTIBODIES | Kymab Limited | JOHNSON, TIRONE DEREK | §102§103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 | |
| 18626784 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | Genzyme Corporation | BRETZ, COREY LANE | §101§102§103§112DP | Non-Final OA | — | Pending | Apr 04, 2024 | |
| 18617239 | NUCLEIC ACIDS ENCODING FACTOR VIII POLYPEPTIDES WITH REDUCED IMMUNOGENICITY | BIOVERATIV THERAPEUTICS INC. | YU, DELPHINUS DOU YI | §102§103§112 | Non-Final OA | — | Pending | Mar 26, 2024 | |
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | Kymab Limited | ROONEY, NORA MAUREEN | 1641 | DP | Final Rejection | 42d overdue | Pending | Feb 29, 2024 |
| 18440711 | BACULOVIRUS EXPRESSION SYSTEM | BIOVERATIV THERAPEUTICS INC. | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18580463 | SCREENING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES | Translate Bio, Inc. | GROSS, CHRISTOPHER M | §102§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 | |
| 18510228 | TREATMENT OF PD-L1 NEGATIVE OR LOW EXPRESSING CANCER WITH ANTI-ICOS ANTIBODIES | Kymab Limited | LI, RUIXIANG | §112 | Non-Final OA | — | Pending | Nov 15, 2023 | |
| 18493991 | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | Ablynx N.V. | DAHLE, CHUN WU | 1641 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18286029 | IMPROVED COMPOSITIONS FOR DELIVERY OF MRNA | Translate Bio, Inc. | ZARA, JANE J | 1637 | §102§103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18463047 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | Genzyme Corporation | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18455756 | TARGETED INHIBITION USING ENGINEERED OLIGONUCLEOTIDES | Mirecule, Inc. | CHONG, KIMBERLY | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18324668 | ANTI-BCMA ANTIBODIES | Sanofi | PETERS, ALEC JON | 1641 | DP | Final Rejection | 16d | Pending | May 26, 2023 |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | HOWARD, ZACHARY C | 1674 | §102§103§112 | Non-Final OA | 127d overdue | Pending | Apr 05, 2023 |
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | Genzyme Corporation | BRETZ, COREY LANE | 1635 | §101§103DP | Final Rejection | 56d | Pending | Apr 05, 2023 |
| 18246263 | PIPERAZINE-BASED CATIONIC LIPIDS | Translate Bio, Inc. | ANDERSON, REBECCA L | 1626 | DP | Final Rejection | 18d overdue | Pending | Mar 22, 2023 |
| 18186856 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | Translate Bio, Inc. | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2023 |
| 18185465 | PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS | Sanofi | HUYNH, PHUONG N | 1641 | Other | Final Rejection | — | Pending | Mar 17, 2023 |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | 4d overdue | Pending | Mar 02, 2023 |
| 18016625 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | Sanofi Pasteur | ROZOF, TIMOTHY R | 1625 | §102§112 | Final Rejection | 6d | Pending | Jan 17, 2023 |
| 18065952 | LARGE-SCALE SYNTHESIS OF MESSENGER RNA | Translate Bio, Inc. | POHNERT, STEVEN C | 1683 | §103§112DP | Final Rejection | — | Pending | Dec 14, 2022 |
| 18052600 | RESPIRATORY SYNCTIAL VIRUS RNA VACCINE | Sanofi | PYLA, EVELYN Y | 1633 | §112DP | Non-Final OA | — | Pending | Nov 04, 2022 |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | Genzyme Corporation | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 26d | Pending | Oct 12, 2022 |
| 17631322 | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR | Translate Bio, Inc. | CONNORS, ALEXANDRA F | 1634 | §112Other | Non-Final OA | — | Pending | Jan 28, 2022 |
| 17576561 | BACULOVIRUS EXPRESSION SYSTEM | BIOVERATIV THERAPEUTICS INC. | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103DP | Non-Final OA | 52d overdue | Pending | Jan 14, 2022 |
| 17615732 | MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS | Regeneron Pharmaceuticals, Inc. | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | — | Pending | Dec 01, 2021 |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Translate Bio, Inc. | POPA, ILEANA | 1633 | §103Other | Non-Final OA | 9d | Pending | Oct 12, 2021 |
| 17472622 | COMPOSITIONS AND METHODS FOR mRNA DELIVERY | Translate Bio, Inc. | KIM, TAEYOON | 1631 | §103 | Final Rejection | — | Pending | Sep 11, 2021 |
| 17344535 | METHODS FOR PURIFICATION OF MESSENGER RNA | Translate Bio, Inc. | LU, FRANK WEI MIN | 1683 | §103§112DP | Non-Final OA | — | Pending | Jun 10, 2021 |
| 17283433 | GENERATION OF IMPROVED HUMAN PAH FOR TREATMENT OF SEVERE PKU BY LIVER-DIRECTED GENE REPLACEMENT THERAPY | Genzyme Corporation | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | — | Pending | Apr 07, 2021 |
| 17185469 | METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER | Sanofi | WEN, SHARON X | 1600 | §103DP | Non-Final OA | — | Pending | Feb 25, 2021 |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | Regeneron Pharmaceuticals, Inc. | FAUST, AMBER KATHLEEN | 1643 | §103 | Non-Final OA | 33d | Pending | Feb 24, 2021 |
| 17112198 | METHODS FOR TREATING COPD BY ADMINISTERING AN IL-33 ANTAGONIST | Regeneron Pharmaceuticals, Inc. | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | — | Pending | Dec 04, 2020 |
| 16863800 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST | Regeneron Pharmaceuticals, Inc. | JOHANSEN, PETER N. | 1644 | §103DP | Final Rejection | — | Pending | Apr 30, 2020 |
| 15034531 | COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME | Regeneron Pharmaceuticals, Inc. | PAK, MICHAEL D | 1674 | §103§112DP | Non-Final OA | — | Pending | May 04, 2016 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial